科济药业(02171.HK) 发盈警，基于CT053的商业化及CT041的新药申请(NDA)获国家药品监督管理局(NMPA)接纳，预期上半年将出现净亏损和经调整净亏损按年减少，料净亏损不超过约8,000万元人民币(下同)，相对于去年同期亏损3.51亿元；经调整净亏损(指不包括以股份为基础的薪酬)的净亏损不超过约7,500万元，去年同期为亏损3.42亿元。
| 公布日期 | 派息事项 | 派息内容 |
|---|---|---|
| 2025/03/18 | 末期业绩 | 无派息 |
| 2024/08/28 | 中期业绩 | 无派息 |
| 2024/03/26 | 末期业绩 | 无派息 |
| 2023/08/22 | 中期业绩 | 无派息 |
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.